Priority Review Vouchers One Step Closer, But Congress Must Act Again
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA guidance on incentive for neglected tropical disease research clarifies some key questions—but also stresses need for appropriation authority to make program work.
You may also be interested in...
Priority Review Vouchers: Coartem And The Importance Of Perceptions
The future of the newly enacted priority review voucher incentive program depends heavily on how the first products to qualify for the award are perceived, BIO Ventures for Global Health CEO Christopher Earl told FDC-Windhover's FDA/CMS Summit for Biopharma Executives Dec. 4
Priority Review Vouchers: Coartem And The Importance Of Perceptions
The future of the newly enacted priority review voucher incentive program depends heavily on how the first products to qualify for the award are perceived, BIO Ventures for Global Health CEO Christopher Earl told FDC-Windhover's FDA/CMS Summit for Biopharma Executives Dec. 4
Priority Review Voucher Program Relies On Perceptions, BVGH Head Warns
Coartem may not be perfect test case for advocates of incentive program.